CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
TNP-2092 +1 moredrug
Likely dose
TNP-2092 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03964493
NCT03964493Phase 2Completed
CompareCT.gov

Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults

TenNor Therapeutics Limited·interventional·Posted May 28, 2019·Updated Dec 1, 2023

In Brief

A Phase 2 clinical trial evaluating TNP-2092 and Vancomycin for Skin and Subcutaneous Tissue Bacterial Infections and Gram-Positive Bacterial Infections. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 28, 2019
Enrollment StartApr 20, 2019
Primary CompletionSep 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.1 years ago

Interventions

TNP-2092drug

TNP-2092 100mg/vial

Vancomycindrug

Vancomycin 1g/vial